The Medical Letter on Drugs and Therapeutics
Dextromethorphan/Quinidine (Nuedexta) for Pseudobulbar Affect
The full article is available to subscribers Subscriber Login   
Revised 7/7/11: "in patients with ALS or MS" was deleted at the end of the first sentence and a new sentence was added to the end of the paragraph. Also, in the Drug Interactions paragraph, the second sentence has been revised.

The FDA has approved Nuedexta (Avanir), a fixed-dose combination of the cough suppressant dextromethorphan hydrobromide and the antiarrhythmic quinidine sulfate, for oral treatment of pseudobulbar affect. The combination is the first treatment approved by the FDA for this indication. Studies to support the effectiveness of Nuedexta were performed in patients with underlying amyotrophic lateral sclerosis (ALS) or multiple sclerosis (MS); the drug has not been shown to be safe or effective in other types of emotional lability.

PSEUDOBULBAR AFFECT — Pseudobulbar affect, also known as pathological laughter and crying or emotional lability, is common in ALS and MS; it is characterized by involuntary, unexpected outbursts of inappropriate laughing or crying. It can also occur in various other neurological conditions, including traumatic brain injury, stroke and Alzheimer’s disease. Standard treatment has ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Immediate Online access to current issue and archives from 1988 to the present
  • Mobile access to our mobile site and free apps for iOS, Android and Kindle
  • FREE online per issue CME/CE
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this article:
Title: Dextromethorphan/Quinidine (Nuedexta) for Pseudobulbar Affect
Article code: 1366b
 Electronic, downloadable article - $25